Want to join the conversation?
$ENDP 2Q15 Call: XIAFLEX had a solid second quarter and remains on track with internal expectation. On a pro forma basis, US sales of XIAFLEX grew 52% compared to 2Q14 in Peyronies disease and Dupuytrens contracture. Approx. 13,000 vials of XIAFLEX were shipped during 2Q15, which is an increase of 6% compared to the same period prior year.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?